Author

W. D. Tilley

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:human· 5 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

L. M. Butler· 3 shared A. R. Hanson· 2 shared C. Y. Mah· 2 shared J. Dehairs· 2 shared J. V. Swinnen· 2 shared L. A. Selth· 2 shared R. Das· 2 shared R. Iggo· 2 shared

Activity by Year

2019-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

L. M. Butler

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

ACSM1 and ACSM3 regulate prostate cancer fatty acid metabolism to promote tumour growth and constrain ferroptosis

R. Shrestha, Z. D. Nassar, A. R. Hanson, R. Iggo, S. L. Townley, J. Dehairs, C. Y. Mah, M. Helm, M. Alizadeh-Ghodsi, M. Pickering, M. J. Watt, L.-E. Quek, A. J. Hoy, W. D. Tilley, J. V. Swinnen, , L. A. Selth

This study identifies ACSM1 and ACSM3 as AR-regulated factors that promote prostate cancer growth by enhancing fatty acid metabolism and suppressing ferroptosis.

bioRxiv · Oct 13, 2022 · PreprintCancer Biology

Lipidomic profiling of clinical prostate cancer reveals targetable alterations in lipid composition

L. M. Butler, C. Y. Mah, J. Machiels, A. D. Vincent, S. Irani, S. Mutuku, X. Spotbeen, M. Bagadi, D. Waltregny, M. Moldovan, J. Dehairs, F. Vanderhoydonc, K. Bloch, R. Das, J. Stahl, , J. V. Swinnen

The paper profiles lipidomes in prostate cancer tissues and identifies targetable lipid alterations linked to AR signaling and therapeutic response.

bioRxiv · Oct 27, 2020Cancer Biology

MDM2 Inhibition in Combination with Endocrine Therapy and CDK4/6 Inhibition for the Treatment of ER-Positive Breast Cancer.

N. Portman, H. H. Milioli, S. Alexandrou, R. Coulson, A. Yong, K. J. Fernandez, K. Chia, D. Segara, A. Parker, S. Haupt, Y. Haupt, W. D. Tilley, A. Swarbrick, C. E. Caldon, E. Lim

This study evaluates MDM2 inhibition combined with endocrine therapy and CDK4/6 inhibition in ER-positive breast cancer, showing synergistic anti-tumor effects in resistant models.

bioRxiv · Jun 9, 2020Cancer Biology

Heparanase promotes Syndecan-1 expression to mediate fibrillar collagen and mammographic density in human breast tissue cultured ex vivo.

X. Huang, G. Reye, K. I. Momot, T. Blick, T. Lloyd, W. D. Tilley, T. E. Hickey, C. E. Snell, R. K. Okolicsanyi, L. M. Haupt, V. Ferro, E. W. Thompson, H. J. Hugo

bioRxiv · Jun 4, 2020Cancer Biology

MicroRNA-194 promotes lineage plasticity in advanced prostate cancer

R. C. Fernandes, J. Toubia, S. Townley, A. R. Hanson, B. K. Dredge, K. A. Pillman, A. G. Bert, R. Iggo, R. Das, MURAL investigators, D. Obinata, S. Sandhu, G. P. Risbridger, R. A. Taylor, M. G. Lawrence, , L. Selth

This study identifies miR-194 as a regulator of lineage plasticity in prostate cancer by targeting FOXA1 and promoting transdifferentiation to a neuroendocrine-like state.

bioRxiv · Sep 12, 2019 · PreprintCancer Biology